CA Patent

CA3094711A1 — Methods of treating ttr amyloidosis using ag10

Assigned to Eidos Therapeutics Inc · Expires 2019-09-26 · 7y expired

What this patent protects

Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.

USPTO Abstract

Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.

Drugs covered by this patent

Patent Metadata

Patent number
CA3094711A1
Jurisdiction
CA
Classification
—
Expires
2019-09-26
Drug substance claim
No
Drug product claim
No
Assignee
Eidos Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.